Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Author(s):
Schoffski, P.; Chawla, S.; Maki, R.G.; Italiano, A.; Gelderblom, H.; Choy, E.; Grignani, G.; Camargo, V.; Bauer, S.; Rha, S.Y.; Blay, J.Y.; Hohenberger, P.; D'Adamo, D.; Guo, M.; Chmielowski, B.; Cesne, A. le; Demetri, G.D.; Patel, S.R.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-04-16
Language
English
Is part of
Lancet (2016), Vol. 387, no. 10028, p. 1629-1637
hdl
1887/112895
doi
10.1016/S0140-6736(15)01283-0